01 August 2023: Database Analysis
Impact of Pre-Transplant Parathyroidectomy on Graft Survival: A Comparative Study of Renal Transplant Patients (2005–2015)
Ming-Hsien Tsai 12ADEF* , Mingchih Chen 34ABD* , Hung-Hsiang Liou 5AD , Tian-Shyug Lee 34B , Yen-Chun Huang 34C , Pei-Yang Liu 6F , Yu-Wei Fang 12AEFG*DOI: 10.12659/MSM.940959
Med Sci Monit 2023; 29:e940959
Table 1 Baseline characteristics between those with/without parathyroidectomy prior kidney transplantation.
| Variables | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| PTx (n=393) | Non-PTx (n=4409) | p value | PTx (n=294) | Non-PTx (n=588) | p value | |
| Male (%) | 155 (42.70) | 2516 (57.07) | 139 (47.28) | 286 (48.64) | 0.703 | |
| Female (%) | 208 (57.30) | 1893 (42.93) | 155 (52.72) | 302 (51.36) | ||
| Age (yr) | 46.89±10.17 | 47.33±11.84 | 0.431 | 46.54±10.11 | 46.66±11.42 | 0.882 |
| 84 (23.14) | 1130 (25.63) | 0.007 | 72 (24.49) | 158 (26.87) | 0.108 | |
| 40–55 (%) | 194 (53.44) | 1989 (45.11) | 156 (53.06) | 269 (45.75) | ||
| ≥55 (%) | 85 (23.42) | 1290 (29.26) | 66 (22.45) | 161 (27.38) | ||
| Dialysis vintage (yr) | 5.69±2.87 | 2.48±2.20 | 4.82±2.45 | 4.81±2.38 | 0.933 | |
| PTx time (yr) | 3.27±2.58 | – | – | 2.84±2.18 | – | – |
| Hemodialysis | 252 (69.42) | 2555 (57.95) | 199 (67.69) | 424 (72.11) | 0.218 | |
| Peritoneal dialysis | 102 (28.10) | 924 (20.96) | 86 (29.25) | 141 (23.98) | ||
| None | 9 (2.48) | 930 (21.09) | 9 (3.06) | 23 (3.91) | ||
| Hypertension (%) | 219 (60.33) | 2517 (57.09) | 0.230 | 174 (59.18) | 333 (56.63) | 0.470 |
| Diabetes mellitus (%) | 122 (33.61) | 1963 (44.52) | 105 (35.71) | 232 (39.46) | 0.281 | |
| Myocardial infarct (%) | 31 (8.54) | 274 (6.21) | 0.082 | 29 (9.86) | 35 (5.95) | 0.035 |
| CHF (%) | 155 (42.70) | 1512 (34.29) | 0.001 | 126 (42.86) | 240 (40.82) | 0.562 |
| Atrial fibrillation (%) | 26 (7.16) | 232 (5.26) | 0.124 | 20 (6.80) | 45 (7.65) | 0.649 |
| PVD (%) | 76 (20.94) | 783 (17.76) | 0.130 | 65 (22.11) | 153 (26.02) | 0.204 |
| COPD (%) | 148 (40.77) | 1495 (33.91) | 0.008 | 120 (40.82) | 194 (32.99) | 0.022 |
| Stroke (%) | 83 (22.87) | 848 (19.23) | 0.093 | 72 (24.49) | 117 (19.90) | 0.117 |
| Hyperlipidemia (%) | 215 (59.23) | 2656 (60.24) | 0.705 | 179 (60.88) | 326 (55.44) | 0.124 |
| Gout (%) | 138 (38.02) | 1738 (39.42) | 0.599 | 113 (38.44) | 207 (35.20) | 0.347 |
| KT with complication (%) | 212 (58.40) | 2278 (51.67) | 0.014 | 180 (61.22) | 305 (51.87) | 0.009 |
| Liver cirrhosis (%) | 26 (7.16) | 334 (7.58) | 0.775 | 23 (7.82) | 36 (6.12) | 0.341 |
| CV intervention | 48 (13.22) | 491 (11.14) | 0.227 | 40 (13.61) | 73 (12.41) | 0.618 |
| ≤3 | 210 (57.85) | 2,862 (64.91) | 173 (58.84) | 347 (59.01) | 0.031 | |
| 4 | 87 (23.97) | 659 (14.95) | 68 (23.13) | 96 (16.33) | ||
| 5 | 33 (9.09) | 417 (9.46) | 25 (8.50) | 63 (10.71) | ||
| 6+ | 33 (9.09) | 471 (10.68) | 28 (9.52) | 82 (13.95) | ||
| ACEI/ARB (%) | 47 (12.95) | 762 (17.28) | 0.034 | 39 (13.27) | 94 (15.99) | 0.287 |
| β-blockers (%) | 69 (19.01) | 1085 (24.61) | 0.017 | 57 (19.39) | 139 (23.64) | 0.152 |
| CCB (%) | 73 (20.11) | 1345 (30.51) | 59 (20.07) | 167 (28.40) | 0.008 | |
| Diuretic (%) | 20 (5.51) | 524 (11.88) | 16 (5.44) | 40 (6.80) | 0.435 | |
| Insulin (%) | 7 (1.93) | 328 (7.44) | 6 (2.04) | 43 (7.31) | 0.001 | |
| Lipid-lowering agents (%) | 53 (14.60) | 626 (14.20) | 0.833 | 41 (13.95) | 80 (13.61) | 0.890 |
| OHA (%) | 11 (3.03) | 365 (8.28) | 10 (3.40) | 46 (7.82) | 0.011 | |
| Benzodiazepine (%) | 92 (25.34) | 955 (21.66) | 0.103 | 71 (24.15) | 139 (23.64) | 0.867 |
| ULA (%) | 29 (7.99) | 511 (11.59) | 0.037 | 26 (8.84) | 33 (5.61) | 0.070 |
| Anticoagulants (%) | 50 (13.77) | 654 (14.83) | 0.584 | 43 (14.63) | 99 (16.84) | 0.400 |
| NSAID (%) | 27 (7.44) | 342 (7.76) | 0.827 | 24 (8.16) | 50 (8.50) | 0.864 |
| PTx – parathyroidectomy; CHF – congestive heart failure; PVD – peripheral vascular disease; COPD – chronic obstructive pulmonary disease; KT – kidney transplants; CV – cardiovascular; CCIS – Charlson comorbidity index score; ACEI – angiotensin-converting enzyme inhibitors; ARB – angiotensin receptor blocker; CCB – calcium channel blocker; OHA – oral hypoglycemic agent; ULA – urine acid-lowering agent; NSAID – non-steroidal anti-inflammatory drug. | ||||||